UroMems has received the 2019 Prix Galien USA Med’Start-Up Award for its collaboration with the Mayo Clinic to design a clinical study for a novel medical device to treat patients with stress urinary incontinence (SUI). The UroMems eAUS device, protected by over 70 patents, is based on the latest technological advances in the field of embedded intelligent software and micro-technologies. It addresses the significant unmet need for a safe, effective, reliable, and seamless solution to treat SUI.
by eazee-designstudio
GTX medical and NeuroRecovery Technologies today announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve functional recovery of people with Spinal Cord Injuries (SCI). The merged entity will be known as GTX medical BV. The Christopher & Dana Reeve Foundation will be a shareholder in the merged company, alongside current investors including LSP, Inkef, Wellington Partners and GIMV. Ian Curtis will join the Board of Directors.
Themis announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur. It was initially developed by Institut Pasteur as part of the ZIKAVAX consortium, coordinated by the European Vaccine Initiative (EVI) and including Themis and the Commissariat à l’énergie atomique et aux énergies alternatives (CEA).
